Lupin Ltd has announced the launch of generic version of its voriconazole tablets and oral suspension that are used to treat fungal infections in children.

The company, after receiving the US Food and Drug Administration’s approval for marketing a generic equivalent of PF Prism CV’s Vfend tablets, 50 mg and 200 mg and Vfend Oral Suspension 40 mg/mL, had launched the same in the US market.

For the patients of 12 years of age and older, the medicines are indicated in the treatment of fungal infections, including invasive Aspergillosis, Candidemia in non-neutropenic patients.

Read EquityPandit’s Nifty Pharma outlook for this week